title: [Rapamycin in the treatment of cardiac rhabdomyoma associated with tuberous sclerosis complex].
abstract: OBJECTIVE
  To assess the efficacy and safety of mammalian target of rapamycin (mTOR) inhibitor rapamycin in treatment of children with cardiac rhabdomyoma, associated with tuberous sclerosis complex (TSC).
  
  
  METHODS
  The clinical data of children with cardiac rhabdomyomas, who had received a diagnosis of TSC previously, were collected between September 2011 and November 2015 from Pediatric Department of the People's Liberation Army General Hospital.Patients in line with the inclusion criteria received long-term treatment with sirolimus.The starting doses of sirolimus was 1 mg/ (m(2)·d), and the plasma concentration was maintained at 5-10 μg/L.The size and number of cardiac rhabdomyomas were analyzed after treatment with rapamycin, and the efficacy and safety were assessed. The Wilcoxon test was used to analyze data.
  
  
  RESULTS
  All the 51 children met the inclusion and exclusion criteria, including 30 males and 21 females.The median age for rapamycin treatment was 15.0 months (7.0-35.0 months). Tumors disappeared in 26 (51%) children, decreased by more than 50%(including 50%) in 15 (29%) children, decreased by less than 50% in 5 (12%) children, and had no change or progressed in 4 (8%) children.The number of tumors decreased by 77(72%). The median maximum diameter of tumor was 8.7 (5.9-11.3) mm before treatment, 0.0 (0.0-4.0) mm after treatment, and the median decrease of tumor size were 6.7 (3.9-10.0) mm (Z=-8.817, P<0.01). The median disappearance time was 3.26 (2.92-5.37) months.Among different age groups, after treatment by rapamycin, the rate of tumor's disappearance was 50% (12/24) in 0-1 years group.Tumors disappeared in 10 of 16 patients in >1-3 years group and in 4 of 11 patients in >3 years group.The rate of tumor's disappearance was the highest after 3 months of treatment as compared with 6 and 12 months of treatment.Ten children had adverse event that was related to rapamycin.Canker sore was reported in one child and dyslipidemia was reported in 9 children.
  
  
  CONCLUSIONS
  Rapamycin is efficacious and well tolerate in treatment of cardiac rhabdomyomas associate with TSC, and lead to a reduction in tumor size and number, in addition, significantly shorten the duration of cardiac rhabdomyoma.
authors.affiliation: Department of Pediatrics, Chinese People's Liberation Army General Hospital, Beijing 100583, China.
authors.forename: L Y
authors.initials: LY
authors.lastname: Pang
authors.forename: L P
authors.initials: LP
authors.lastname: Zou
authors.forename: L L
authors.initials: LL
authors.lastname: Huang
authors.forename: Y
authors.initials: Y
authors.lastname: Gao
authors.forename: S F
authors.initials: SF
authors.lastname: Ma
authors.forename: M N
authors.initials: MN
authors.lastname: Zhang
authors.forename: Y Y
authors.initials: YY
authors.lastname: Wang
mesh_terms: D002675:Child, Preschool; D005260:Female; D006338:Heart Neoplasms / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D012207:Rhabdomyoma / Q000188:drug therapy*; D020123:Sirolimus / Q000627:therapeutic use*; D014402:Tuberous Sclerosis / Q000188:drug therapy*
chemical_list: D020123:Sirolimus